Banque Cantonale Vaudoise Akero Therapeutics, Inc. Transaction History
Banque Cantonale Vaudoise
- $2.52 Billion
- Q2 2024
A detailed history of Banque Cantonale Vaudoise transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Banque Cantonale Vaudoise holds 1,000 shares of AKRO stock, worth $28,690. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,000
Previous 1,000
-0.0%
Holding current value
$28,690
Previous $25,000
8.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding AKRO
# of Institutions
168Shares Held
72.7MCall Options Held
178KPut Options Held
164K-
Janus Henderson Group PLC London, X06.88MShares$197 Million0.09% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$160 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.43MShares$156 Million2.13% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$150 Million3.88% of portfolio
-
Wellington Management Group LLP Boston, MA5.11MShares$147 Million0.02% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $1.33B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...